Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review

Abstract : Background
Open-label, randomized controlled trials (RCTs) are subject to observer bias. If patient management is conducted without blinding, a difference between groups may be explained by other factors than study treatment. One factor may come from taking concomitant treatments with an efficacy on the studied outcomes. In type 2 diabetes, some antihypertensive or lipid-lowering drugs are effective against diabetic complications. We wanted to determine if these concomitant treatments were correctly reported in articles of RCTs on type 2 diabetes and if they might have influenced the outcome.
Methods
We performed a systematic review using Medline, Embase, and the Cochrane Library (from January 1950 to July 2010). Open-label RCTs assessing the effectiveness of intensive blood-glucose control in type 2 diabetes were included. We chose five therapeutic classes with proven efficacy against diabetes complications: angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (AIIRAs), fibrates, statins, and aspirin. Differences between concomitant treatments were considered statistically significant when p < 0.05.
Results
A total of eight open-label RCTs were included, but only three (37.5%) of them published concomitant treatments. In two studies (ACCORD and ADVANCE), a statistically significant difference was observed between the two groups for aspirin (p = 0.02) and ACEIs (p = 0.02).
Conclusions
Few concomitant treatments were published in this sample of open-label RCTs. We cannot completely eliminate an observer bias for these studies. This bias probably influenced the results to an extent that has yet to be determined.
Type de document :
Article dans une revue
BMC Medical Research Methodology, BioMed Central, 2013, 13 (1), pp.107
Liste complète des métadonnées

Littérature citée [28 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00868747
Contributeur : Ed. Bmc <>
Soumis le : mardi 1 octobre 2013 - 21:29:57
Dernière modification le : mardi 24 avril 2018 - 13:52:17
Document(s) archivé(s) le : lundi 6 janvier 2014 - 09:40:09

Fichiers

Identifiants

  • HAL Id : inserm-00868747, version 1

Collections

Citation

Rémy Boussageon, Irène Supper, Sylvie Erpeldinger, Michel Cucherat, Theodora Bejan-Angoulvant, et al.. Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review. BMC Medical Research Methodology, BioMed Central, 2013, 13 (1), pp.107. 〈inserm-00868747〉

Partager

Métriques

Consultations de la notice

364

Téléchargements de fichiers

146